Importance: Identifying clinical change in many neurologic diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), can be challenging. At the same time, how change is defined heavily influences a patient's diagnostic and treatment pathway. It can be especially problematic when equivocal subjective observations are interpreted as clinically meaningful and then used to make diagnostic and treatment decisions. Change in clinical trials is strictly defined by a preselected metric, but there is a perception that formal outcomes collection during routine clinical care is neither feasible nor necessary. Given the importance placed on how change is interpreted, there is a need to select assessments that can be applied to routine care that are representative of the neurologic disease state. Observations: For an outcome measure to be useful during clinical trials, it must have good reliability, validity, be responsive to change, and have clinical meaning. To be useful during routine clinical care, the assessment must additionally be easy to collect without the need for extensive training or equipment and should provide an immediately available result that can be rapidly quantified and interpreted. Chronic inflammatory demyelinating polyneuropathy is clinically heterogeneous and so is best evaluated with a diverse group of assessment tools. Assessing strength impairment, disability, and quality of life is ideally suited for everyday practice when caring for patients with CIDP. While electrophysiologic studies, imaging, cerebrospinal fluid, and nodal/paranodal antibodies can provide diagnostic data, they are less practical and helpful longitudinal assessment tools. Conclusions and Relevance: Sound clinimetric outcome measures in CIDP are widely available and have the potential to help clinicians objectify treatment response and disease progression. Such data are critically important when justifying the need for ongoing or periodic immunotherapy, documenting relapse or deterioration, or providing reassurance of disease improvement, stability, or remission.
Bibliographical noteFunding Information:
nonfinancial support from Meridian HealthComms during the conduct of the study; personal fees from CSL Behring, Alexion, Biotest, Akcea, and Argenyx outside the submitted work. Dr Merkies reported grants from Talecris Talents Program, GBS CIDP Foundation International, and the FP7 EU programme outside the submitted work. Dr Lewis reported personal fees from CSL Behring, Argenx, Akcea, Alnylam, Annexon, Biotest, Momenta, Pfizer, and Sanofi outside the submitted work. No other disclosures were reported.
Additional Contributions: Editorial support was provided by Meridian HealthComms Ltd. Funding for editorial support was provided by CSL Behring.
© 2020 American Medical Association. All rights reserved.
PubMed: MeSH publication types
- Journal Article